Researchers at Mayo Clinic have found patients who use gastric suppression medications are at a higher risk for recurrent Clostridium difficile (C. diff) infection. C. diff is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. The study is published in JAMA Internal Medicine.
"In our study, we found that use of gastric acid suppression medications are associated with a statistically significant increased risk of development of recurrent C. diff in patients with a prior episode of C. diff," says Sahil Khanna, MBBS, a gastroenterologist at Mayo Clinic and senior author of the study.
Khanna says gastric suppression medications studied include proton pump inhibitors, such as omeprazole, and histamine 2 blockers, such as ranitidine, which are commonly prescribed and consumed over-the-counter medications for gastroesophageal reflux disease, peptic ulcer disease or dyspepsia.
In a systematic review and meta-analysis of 16 studies with 7,703 patients with C. diff, 1,525 developed recurrent C. diff. The rate of recurrent C. diff in patients with gastric suppression was 22.1 percent, compared to 17.3 percent in patients without gastric acid suppression.
Khanna urges caution in interpreting these findings due to variables not considered in the study, such as the underlying reason why the gastric acid suppressant was needed. However, he says the findings suggest that patients with C. diff who receive gastric acid suppressants may be at increased risk of C-diff recurrence. "It may be reasonable to re-evaluate the need for these medications in patients with . diff," Khanna says.
Source: Mayo Clinic
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
US Withdrawal From UNESCO Signals a Dangerous Step Back for Global Science
July 22nd 2025In a decision heavy with consequence and light on foresight, the US has once again chosen to walk away from UNESCO, leaving behind not just a seat at the table, but a legacy of global scientific leadership that now lies in question.
Breaking the Cycle of Silence: Why Sharps Injuries Go Unreported and What Can Be Done
Published: July 24th 2025 | Updated: July 23rd 2025Despite decades of progress in health care safety, a quiet but dangerous culture still lingers: many health care workers remain afraid to report sharps injuries, fearing blame more than the wound itself.
Telemedicine's Transformative Role in PPE Distribution and Sterile Equipment Management
July 22nd 2025In an era defined by digital transformation and post-pandemic urgency, telemedicine has evolved beyond virtual visits to become a vital infrastructure for delivering personal protective equipment (PPE) and managing sterile supplies. By enabling real-time forecasting, remote quality control, and equitable distribution, telemedicine is revolutionizing how health care systems protect both patients and providers.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.